Experimental Carbonic Anhydrase Inhibitors for the Treatment of Hypoxic Tumors

References

• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314. doi:10.1126/science.123.3191.309
   PubMed Web of Science ®Google Scholar
• Semenza GL. Pharmacologic targeting of hypoxia-inducible factors. Annu Rev Pharmacol Toxicol. 2019;59:379–403.
   PubMed Web of Science ®Google Scholar
• Pugh CW, Ratcliffe PJ. New horizons in hypoxia signaling pathways. Exp Cell Res. 2017;356:116–121.
   PubMed Web of Science ®Google Scholar
• Kaelin WG. The VHL tumor suppressor gene: insights into oxygen sensing and cancer. Trans Am Clin Climatol Assoc. 2017;128:298–307.
   PubMedGoogle Scholar
• Schito L, Semenza GL. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer. 2016;2:758–770.
   PubMed Web of Science ®Google Scholar
• Ebbesen P, Pettersen EO, Gorr TA, et al. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies. J Enzyme Inhib Med Chem. 2009;24(Suppl 1):1–39.
   PubMed Web of Science ®Google Scholar
• Schwartz L, Supuran CT, Alfarouk KO. The Warburg effect and the hallmarks of cancer. Anticancer Agents Med Chem. 2017;17:164–170.
   PubMed Web of Science ®Google Scholar
• Pettersen EO, Ebbesen P, Gieling RG, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem. 2015;30(5):689–721.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60:7075–7083.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Beasley N, Watson PH, et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol. 2001;158(3):1011–1019. doi:10.1016/S0002-9440(10)64048-5
   Web of Science ®Google Scholar
• Beasley NJ, Wykoff CC, Watson PH, et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 2001;61:5262–5267.
   PubMed Web of Science ®Google Scholar
• Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001;61:6394–6399.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 2001;61:7992–7998.
   PubMed Web of Science ®Google Scholar
• Turner KJ, Crew JP, Wykoff CC, et al. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer. 2002;86:1276–1282.
   PubMed Web of Science ®Google Scholar
• Mandriota SJ, Turner KJ, Davies DR, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell. 2002;1:459–468.
   PubMed Web of Science ®Google Scholar
• Stessels F, Van den Eynden G, Van der Auwera I, et al. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer. 2004;90:1429–1436.
   PubMed Web of Science ®Google Scholar
• Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001;19:3660–3668.
   PubMed Web of Science ®Google Scholar
• Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437–443.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10:767–777.
   PubMed Web of Science ®Google Scholar
• Beaney RP. Positron emission tomography in the study of human tumors. Semin Nucl Med. 1984;14(4):324–341.
   PubMed Web of Science ®Google Scholar
• Nanni C, Zamagni E. Fluorodeoxyglucose-PET/Computed Tomography as a Predictor of Prognosis in Multiple Myeloma. PET Clin. 2019;14(3):383–389.
   Web of Science ®Google Scholar
• Rubello D, Marzola MC, Colletti PM. The Prognostic Value of 18F-FDG PET/CT in Monitoring Chemotherapy in Ovarian Cancer Both at Initial Diagnosis and at Recurrent Disease. Clin Nucl Med. 2018;43(10):735–738.
   Web of Science ®Google Scholar
• Kozaka K, Kobayashi S, Takamura H, et al. Differences in 18F-FDG Uptake and Expression of Glucose Transporter Between 2 Distinct Subtypes of Mass-Forming Intrahepatic Cholangiocarcinomas. Clin Nucl Med. 2020;45(6):e267–e273.
   Web of Science ®Google Scholar
• Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther. 2003;3(2):263–276.
   PubMed Web of Science ®Google Scholar
• Singh N, Badrun D, Ghatage P. State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer. Expert Opin Pharmacother. 2020;21(13):1579–1590.
   PubMed Web of Science ®Google Scholar
• De Luca E, Marino D, Di Maio M. Ramucirumab, a second-line option for patients with hepatocellular carcinoma: a review of the evidence. Cancer Manag Res. 2020;12:3721–3729.
   PubMed Web of Science ®Google Scholar
• Papachristos A, Sivolapenko GB, Pharmacogenomics P. Circulating proteins as biomarkers for bevacizumab treatment optimization in patients with cancer: a review. J Pers Med. 2020;10(3):E79.
   Web of Science ®Google Scholar
• Chafe SC, McDonald PC, Dedhar S. pH regulators of the tumor microenvironment. A general overview. In: Supuran CT, Carradori S, editors. Ph-Interfering Agents as Chemosensitizers in Cancer Therapy. London, UK: Elsevier; 2021:13–33.
   Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7:168–181.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Structure and function of carbonic anhydrases. Biochem J. 2016;473:2023–2032.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT. Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. Expert Opin Drug Discov. 2019;14:1175–1197.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov. 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov. 2020;15(6):671–686.
   PubMed Web of Science ®Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem. 2016;31:345–360.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat. 2018;28:709–712.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Supuran CT, Carta F. Antiobesity carbonic anhydrase inhibitors: a literature and patent review. Expert Opin Ther Pat. 2013;23:725–735.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opin Ther Pat. 2018;28:713–721.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Altamimi ASA, Carta F. Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013–2019. Expert Opin Ther Pat. 2019;29:781–792.
   PubMed Web of Science ®Google Scholar
• Supuran CT. The management of glaucoma and macular degeneration. Expert Opin Ther Pat. 2019;29:745–747.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibition and the management of neuropathic pain. Expert Rev Neurother. 2016;16:961–968.
   PubMed Web of Science ®Google Scholar
• Di Cesare Mannelli L, Micheli L, Carta F, et al. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. Enzyme Inhib Med Chem. 2016;31:894–899.
   PubMed Web of Science ®Google Scholar
• Margheri F, Ceruso M, Carta F, et al. Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium. J Enzyme Inhib Med Chem. 2016;31(sup4):60–63.
   PubMed Web of Science ®Google Scholar
• Bua S. Design and Synthesis of Novel Nonsteroidal Anti-Inflammatory Drugs and Carbonic Anhydrase Inhibitors Hybrids (NSAIDs-CAIs) for the Treatment of Rheumatoid Arthritis. J Med Chem. 2017;60:1159–1170.
   PubMed Web of Science ®Google Scholar
• Kaur J, Cao X, Abutaleb NS, et al. Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant Enterococcus. J Med Chem. 2020;63(17):9540–9562.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Capasso C. Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Expert Opin Ther Pat. 2020;1–20. doi:10.1080/13543776.2020.1811853
   Web of Science ®Google Scholar
• Vermelho AB, Rodrigues GC, Supuran CT. Why hasn’t there been more progress in new Chagas disease drug discovery? Expert Opin Drug Discov. 2020;15(2):145–158.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Capasso C. Biomedical applications of prokaryotic carbonic anhydrases. Expert Opin Ther Pat. 2018;28(10):745–754.
   PubMed Web of Science ®Google Scholar
• Capasso C, Supuran CT. Bacterial, fungal and protozoan carbonic anhydrases as drug targets. Expert Opin Ther Targets. 2015;19(12):1689–1704.
   PubMed Web of Science ®Google Scholar
• Supuran CT, The CC. η-class carbonic anhydrases as drug targets for antimalarial agents. Expert Opin Ther Targets. 2015;19(4):551–563.
   PubMed Web of Science ®Google Scholar
• Capasso C, Supuran CT. Anti-infective carbonic anhydrase inhibitors: a patent and literature review. Expert Opin Ther Pat. 2013;23(6):693–704.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors. Expert Opin Investig Drugs. 2018;27(12):963–970.
   PubMed Web of Science ®Google Scholar
• Berrino E, Supuran CT. Novel approaches for designing drugs that interfere with pH regulation. Expert Opin Drug Discov. 2019;14(3):231–248.
   PubMed Web of Science ®Google Scholar
• Angeli A, Carta F, Nocentini A, et al. Carbonic Anhydrase Inhibitors Targeting Metabolism and Tumor Microenvironment. Metabolites. 2020;10(10):E412.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Anhydrase C. Inhibition and the Management of Hypoxic Tumors. Metabolites. 2017;7(3):48.
   Web of Science ®Google Scholar
• Iessi E, Logozzi M, Mizzoni D, Di Raimo R, Supuran CT, Fais S. Rethinking the Combination of Proton Exchanger Inhibitors in Cancer Therapy. Metabolites. 2017;8(1):2.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Swayampakula M, Dedhar S. Coordinated Regulation of Metabolic Transporters and Migration/Invasion by Carbonic Anhydrase IX. Metabolites. 2018;8(1):20.
   PubMed Web of Science ®Google Scholar
• Benej M, Svastova E, Banova R, et al. Intracellular pH to Maintain Metabolic Reprogramming and Proliferation in Hypoxia. Front Oncol. 2020;2(10):1462.
   Web of Science ®Google Scholar
• Pastorek J, Pastoreková S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 1994;9:2877–2888.
   PubMed Web of Science ®Google Scholar
• Türeci O, Sahin U, Vollmar E, et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci U S A. 1998;95:7608–7613.
   PubMed Web of Science ®Google Scholar
• Svastová E, Hulíková A, Rafajová M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004;577:439–445.
   PubMed Web of Science ®Google Scholar
• Cecchi A, Hulikova A, Pastorek J, et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem. 2005;48:4834–4841.
   PubMed Web of Science ®Google Scholar
• Swietach P, Wigfield S, Cobden P, et al. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem. 2008;283:20473–20483.
   PubMed Web of Science ®Google Scholar
• Swietach P, Patiar S, Supuran CT, et al. The role of carbonic anhydrase 9 in regulating extracellular and intracellular pH in three-dimensional tumor cell growths. J Biol Chem. 2009;284:20299–20310.
   PubMed Web of Science ®Google Scholar
• Ahlskog JK, Dumelin CE, Trüssel S, Mårlind J, Neri D. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett. 2009;19(16):4851–4856.
   PubMed Web of Science ®Google Scholar
• Buller F, Steiner M, Frey K, et al. Selection of Carbonic Anhydrase IX Inhibitors from One Million DNA-Encoded Compounds. ACS Chem Biol. 2001;6(4):336–344.
   Web of Science ®Google Scholar
• Krall N, Pretto F, Decurtins W, Bernardes GJ, Supuran CT, Neri D. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl. 2014;53(16):4231–4235.
   PubMed Web of Science ®Google Scholar
• Krall N, Pretto F, Mattarella M, Müller C, Neri D. A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo. J Nucl Med. 2016;57(6):943–949.
   PubMed Web of Science ®Google Scholar
• Cazzamalli S, Dal Corso A, Neri D. Acetazolamide Serves as Selective Delivery Vehicle for Dipeptide-Linked Drugs to Renal Cell Carcinoma. Mol Cancer Ther. 2016;15(12):2926–2935.
   Web of Science ®Google Scholar
• Cazzamalli S, Dal Corso A, Widmayer F, Neri D. Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis. J Am Chem Soc. 2018;140(5):1617–1621.
   PubMed Web of Science ®Google Scholar
• Cazzamalli S, Ziffels B, Widmayer F, et al. Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2. Clin Cancer Res. 2018;24(15):3656–3667.
   PubMed Web of Science ®Google Scholar
• Cazzamalli S, Figueras E, Pethő L, et al. In Vivo Antitumor Activity of a Novel Acetazolamide-Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas. ACS Omega. 2018;3(11):14726–14731.
   PubMed Web of Science ®Google Scholar
• Gouyou B, Millul J, Villa A, Cazzamalli S, Neri D, Sortase-Mediated Site-Specific MM. Modification of Interleukin-2 for the Generation of a Tumor-Targeting Acetazolamide-Cytokine Conjugate. ACS Omega. 2020;5(40):26077–26083.
   PubMed Web of Science ®Google Scholar
• Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring? J Med Chem. 1999;42:2641–2650.
   PubMed Web of Science ®Google Scholar
• Dubois L, Peeters SG, van Kuijk SJ, et al. Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs. Radiother Oncol. 2013;108(3):523–528.
   PubMed Web of Science ®Google Scholar
• Rami M, Dubois L, Parvathaneni NK, et al. Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates. J Med Chem. 2013;56(21):8512–8520.
   PubMed Web of Science ®Google Scholar
• van Kuijk SJA, Parvathaneni NK, Niemans R, et al. New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs. Eur J Med Chem. 2017;15(127):691–702.
   Web of Science ®Google Scholar
• Aspatwar A, Becker HM, Parvathaneni NK, et al. Nitroimidazole-based inhibitors DTP338 and DTP348 are safe for zebrafish embryos and efficiently inhibit the activity of human CA IX in Xenopus oocytes. J Enzyme Inhib Med Chem. 2018;33(1):1064–1073.
   PubMed Web of Science ®Google Scholar
• Aspatwar A, Parvathaneni NK, Barker H, et al. Design, synthesis, in vitro inhibition and toxicological evaluation of human carbonic anhydrases I, II and IX inhibitors in 5-nitroimidazole series. J Enzyme Inhib Med Chem. 2020;35(1):109–117.
   PubMed Web of Science ®Google Scholar
• Anduran E, Aspatwar A, Parvathaneni NK, et al. Hypoxia-Activated Prodrug Derivatives of Carbonic Anhydrase Inhibitors in Benzenesulfonamide Series: synthesis and Biological Evaluation. Molecules. 2020;25(10):2347.
   PubMed Web of Science ®Google Scholar
• Gieling RG, Babur M, Mamnani L, et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem. 2012;55(11):5591–5600.
   PubMed Web of Science ®Google Scholar
• Bryant JL, Gieling RG, Meredith SL, et al. Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer. Int J Cancer. 2018;142(1):191–201.
   PubMed Web of Science ®Google Scholar
• Wilkinson BL, Bornaghi LF, Houston TA, Innocenti A, Supuran CT, Poulsen SA. A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by “click-tailing”. J Med Chem. 2006;49(22):6539–6548.
   PubMed Web of Science ®Google Scholar
• Wilkinson BL, Bornaghi LF, Houston TA, et al. Carbonic anhydrase inhibitors: inhibition of isozymes I, II, and IX with triazole-linked O-glycosides of benzene sulfonamides. J Med Chem. 2007;50(7):1651–1657.
   Web of Science ®Google Scholar
• Wilkinson BL, Innocenti A, Vullo D, Supuran CT, Poulsen SA. Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. J Med Chem. 2008;51(6):1945–1953.
   Web of Science ®Google Scholar
• Lopez M, Paul B, Hofmann A, et al. S-glycosyl primary sulfonamides–a new structural class for selective inhibition of cancer-associated carbonic anhydrases. J Med Chem. 2009;52(20):6421–6432.
   PubMed Web of Science ®Google Scholar
• Lopez M, Bornaghi LF, Innocenti A, et al. Sulfonamide linked neoglycoconjugates–a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010;53(7):2913–2926.
   PubMed Web of Science ®Google Scholar
• Morris JC, Chiche J, Grellier C, et al. Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. J Med Chem. 2011;54(19):6905–6918.
   Web of Science ®Google Scholar
• Lounnas N, Rosilio C, Nebout M, et al. Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas. Cancer Lett. 2013;333(1):76–88.
   Web of Science ®Google Scholar
• Tanpure RP, Ren B, Peat TS, Bornaghi LF, Vullo D, Supuran CT. Carbonic anhydrase inhibitors with dual-tail moieties to match the hydrophobic and hydrophilic halves of the carbonic anhydrase active site. J Med Chem. 2015;58(3):1494–1501.
   PubMed Web of Science ®Google Scholar
• Moeker J, Peat TS, Bornaghi LF, Vullo D, Supuran CT, Poulsen SA. Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes. J Med Chem. 2014;57(8):3522–3531.
   PubMed Web of Science ®Google Scholar
• Köhler K, Hillebrecht A, Schulze Wischeler J, et al. Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. Angew Chem Int Ed Engl. 2007;46(40):7697–7699.
   PubMed Web of Science ®Google Scholar
• Sneddon D, Niemans R, Bauwens M, et al. Synthesis and in Vivo Biological Evaluation of (68)Ga-Labeled Carbonic Anhydrase IX Targeting Small Molecules for Positron Emission Tomography. J Med Chem. 2016;59(13):6431–6443.
   PubMed Web of Science ®Google Scholar
• Pan J, Lau J, Mesak F, et al. Synthesis and evaluation of 18F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography. J Enzyme Inhib Med Chem. 2014;29(2):249–255.
   PubMed Web of Science ®Google Scholar
• Lau J, Zhang Z, Jenni S, et al. Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with (68)Ga-Labeled Benzenesulfonamides. Mol Pharm. 2016;13(3):1137–1146.
   Web of Science ®Google Scholar
• Zhang Z, Lau J, Zhang C, et al. Design, synthesis and evaluation of 18F-labeled cationic carbonic anhydrase IX inhibitors for PET imaging. J Enzyme Inhib Med Chem. 2017;32(1):722–730.
   PubMed Web of Science ®Google Scholar
• Mujumdar P, Teruya K, Tonissen KF, Vullo D, Supuran CT, Peat TS. An Unusual Natural Product Primary Sulfonamide: synthesis, Carbonic Anhydrase Inhibition, and Protein X-ray Structures of Psammaplin C. J Med Chem. 2016;59(11):5462–5470.
   Web of Science ®Google Scholar
• Mujumdar P, Kopecka J, Bua S, Supuran CT, Riganti C. Poulsen SA.Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma. J Med Chem. 2019;62(8):4174–4192.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem. 2011;54(6):1896–1902.
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011;71(9):3364–3376.
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun (Camb). 2010;46(44):8371–8373.
   PubMed Web of Science ®Google Scholar
• Touisni N, Maresca A, McDonald PC, et al. Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors. J Med Chem. 2011;54(24):8271–8277. doi:10.1021/jm200983e
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Vu H, et al. Non-Zinc Mediated Inhibition of Carbonic Anhydrases: coumarins Are a New Class of Suicide Inhibitors #. J Am Chem Soc. 2009;131(8):3057–3062. doi:10.1021/ja809683v
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Pochet L, Masereel B, Scozzafava A, Supuran CT. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010;53(1):335–344. doi:10.1021/jm901287j
   PubMed Web of Science ®Google Scholar
• McDonald PC, Winum J-Y, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget. 2012;3(1):84–97. doi:10.18632/oncotarget.422
   PubMed Web of Science ®Google Scholar
• Lock FE, McDonald PC, Lou Y, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 2013;32(44):5210–5219. doi:10.1038/onc.2012.550
   PubMed Web of Science ®Google Scholar
• Swayampakula M, McDonald PC, Vallejo M, et al. The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion. Oncogene. 2017;36(45):6244–6261.
   Web of Science ®Google Scholar
• Bozdag M, Carta F, Ceruso M, et al. Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 Analogues for the Treatment of Hypoxic Tumors Overexpressing Carbonic Anhydrase IX. J Med Chem. 2018;61(14):6328–6338. doi:10.1021/acs.jmedchem.8b00770
   PubMed Web of Science ®Google Scholar
• McDonald PC, Chafe SC, Brown WS, et al. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. Gastroenterology. 2019;157(3):823–837.
   PubMed Web of Science ®Google Scholar
• Chafe SC, McDonald PC, Saberi S, et al. Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically. Cancer Immunol Res. 2019;7(7):1064–1078. doi:10.1158/2326-6066.CIR-18-0657
   PubMed Web of Science ®Google Scholar
• Boyd NH, Walker K, Fried J, et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight. 2017;2(24):92928. doi:10.1172/jci.insight.92928
   PubMed Web of Science ®Google Scholar
• Kuchuk O, Tuccitto A, Citterio D, et al. pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma. Oncoimmunology. 2018;7(7):e1445452. doi:10.1080/2162402X.2018.1445452
   PubMed Web of Science ®Google Scholar
• Ward C, Meehan J, Gray M, et al. Carbonic Anhydrase IX (CAIX), Cancer, and Radiation Responsiveness. Metabolites. 2018;8(1):E13. doi:10.3390/metabo8010013
   Web of Science ®Google Scholar
• Federici C, Lugini L, Marino ML, et al. Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells. J Enzyme Inhib Med Chem. 2016;31(sup1):119–125. doi:10.1080/14756366.2016.1177525
   PubMed Web of Science ®Google Scholar
• Andreucci E, Peppicelli S, Carta F, et al. Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis. J Mol Med (Berl). 2017;95(12):1341–1353. doi:10.1007/s00109-017-1590-9
   PubMed Web of Science ®Google Scholar
• Logsdon DP, Grimard M, Luo M, et al. Regulation of HIF1 under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: dual Targeting in Patient-Derived 3D Pancreatic Cancer Models. Mol Cancer Ther. 2016;15(11):2722–2732. doi:10.1158/1535-7163.MCT-16-0253
   Web of Science ®Google Scholar
• Peppicelli S, Andreucci E, Ruzzolini J, et al. The Carbonic Anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells. J Enzyme Inhib Med Chem. 2020;35(1):1185–1193. doi:10.1080/14756366.2020.1764549
   PubMed Web of Science ®Google Scholar
• Genah S, Angeli A, Supuran CT, Morbidelli L. Effect of Carbonic Anhydrase IX inhibitors on human endothelial cell survival. Pharmacol Res. 2020;159:104964. doi:10.1016/j.phrs.2020.104964
   PubMed Web of Science ®Google Scholar
• Riemann A, Güttler A, Haupt V, et al. Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does Not Modulate Daunorubicin or Cisplatin Cytotoxicity. Oncol Res. 2018;26(2):191–200. doi:10.3727/096504017X14965111926391
   PubMed Web of Science ®Google Scholar
• Güttler A, Theuerkorn K, Riemann A, et al. Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells. Oncol Rep. 2019;41(4):2585–2594.
   Web of Science ®Google Scholar
• Lee JY, Alexeyev M, Kozhukhar N, Pastukh V, White R, Stevens T. Carbonic anhydrase IX is a critical determinant of pulmonary microvascular endothelial cell pH regulation and angiogenesis during acidosis. Am J Physiol Lung Cell Mol Physiol. 2018;315(1):L41–L51.
   Web of Science ®Google Scholar
• Lee JY, Onanyan M, Garrison I, et al. Extrinsic acidosis suppresses glycolysis and migration while increasing network formation in pulmonary microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2019;317(2):L188–L201.
   Web of Science ®Google Scholar
• Bernardino RL, Dias TR, Moreira BP, et al. Carbonic anhydrases are involved in mitochondrial biogenesis and control the production of lactate by human Sertoli cells. FEBS J. 2019;286(7):1393–1406.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Chia S, Bedard PL, et al. A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors. Am J Clin Oncol. 2020;43(7):484–490.
   PubMed Web of Science ®Google Scholar
• Akocak S, Lolak N, Bua S, Turel I, Supuran CT. Synthesis and biological evaluation of novel N, N’-diaryl cyanoguanidines acting as potent and selective carbonic anhydrase II inhibitors. Bioorg Chem. 2018;77:245–251. doi:10.1016/j.bioorg.2018.01.022;
   PubMed Web of Science ®Google Scholar
• Lolak N, Akocak S, Bua S, Koca M, Supuran CT. Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors. Bioorg Chem. 2018;77:542–547. doi:10.1016/j.bioorg.2018.02.015
   PubMed Web of Science ®Google Scholar
• Lomelino CL, Mahon BP, Carta F, Supuran CT, Kinetic MR. and X-ray crystallographic investigations on carbonic anhydrase isoforms I, II, IX and XII of a thioureido analog of SLC-0111 Bioorg. Med Chem. 2016;24:976–981. doi:10.1016/j.bmc.2016.01.019;
   Web of Science ®Google Scholar
• Angeli A, Tanini D, Peat TS, et al. Discovery of new selenoureido analogues of 4-(4-fluorophenylureido) benzenesulfonamide as carbonic anhydrase inhibitors ACS Med. Chem Lett. 2017;8:963–968. doi:10.1021/acsmedchemlett.7b00280
   Web of Science ®Google Scholar
• Eldehna WM, Abo-Ashour MF, Berrino E, et al. SLC-0111 enaminone analogs, 3/4-(3-aryl-3-oxopropenyl) aminobenzenesulfonamides, as novel selective subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform IX. Bioorg Chem. 2019;83:549–558. doi:10.1016/j.bioorg.2018.11.014
   PubMed Web of Science ®Google Scholar
• Congiu C, Onnis V, Deplano A, Balboni G, Dedeoglu N, Supuran CT. Synthesis of sulfonamides incorporating piperazinyl-ureido moieties and their carbonic anhydrase I, II, IX and XII inhibitory activity. Bioorg Med Chem Lett. 2015;25(18):3850–3853.
   PubMed Web of Science ®Google Scholar
• Moi D, Nocentini A, Deplano A, et al. Appliance of the piperidinyl-hydrazidoureido linker to benzenesulfonamide compounds: synthesis, in vitro and in silico evaluation of potent carbonic anhydrase II, IX and XII inhibitors. Bioorg Chem. 2020;98:103728.
   PubMed Web of Science ®Google Scholar
• Abo-Ashour MF, Eldehn WM, Nocentini A, et al. Novel synthesized SLC-0111 thiazole and thiadiazole analogues: determination of their carbonic anhydrase inhibitory activity and molecular modeling studies. Bioorg Chem. 2019;87:794–802. doi:10.1016/j.bioorg.2019.04.002.
   PubMed Web of Science ®Google Scholar
• Alkhaldi AAM, Al-Sanea MM, Nocentini A, et al. 3-Methylthiazolo[3,2-a]benzimidazole-benzenesulfonamide conjugates as novel carbonic anhydrase inhibitors endowed with anticancer activity: design, synthesis, biological and molecular modeling studies. Eur J Med Chem. 2020;207:112745.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Fares M, Ceruso M, et al. Amido/ureidosubstituted benzenesulfonamides-isatin conjugates as low nanomolar/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII. Eur J Med Chem. 2016;110:259–266.
   PubMed Web of Science ®Google Scholar
• Eldehna WM, Abo-Ashour MF, Nocentini A, et al. Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents. Eur J Med Chem. 2019;162:147e160.
   Web of Science ®Google Scholar
• Iikuni S, Ono M, Watanabe H, Shimizu Y, Sano K, Saji H. Cancer radiotheranostics targeting carbonic anhydrase-IX with 111In- and 90Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy. Theranostics. 2018;8(11):2992–3006.
   PubMed Web of Science ®Google Scholar
• Andring JT, Fouch M, Akocak S, et al. Structural Basis of Nanomolar Inhibition of Tumor-Associated Carbonic Anhydrase IX: X-Ray Crystallographic and Inhibition Study of Lipophilic Inhibitors with Acetazolamide Backbone. J Med Chem. 2020. doi:10.1021/acs.jmedchem.0c01390
   Web of Science ®Google Scholar
• Bonardi A, Nocentini A, Bua S, et al. Sulfonamide inhibitors of human carbonic anhydrases designed through a three-tails approach: improving ligand/isoform matching and selectivity of action. J Med Chem. 2020;63(13):7422–7444.
   PubMed Web of Science ®Google Scholar
• Petreni A, Bonardi A, Lomelino C, Osman SM. Inclusion of a 5-fluorouracil moiety in nitrogenous bases derivatives as human carbonic anhydrase IX and XII inhibitors produced a targeted action against MDA-MB-231 and T47D breast cancer cells. Eur J Med Chem. 2020;190:112112.
   PubMed Web of Science ®Google Scholar
• Bua S, Lomelino C, Murray AB, Osman SM. “A sweet combination”: developing saccharin and acesulfame k structures for selectively targeting the tumor-associated carbonic anhydrases IX and XII. J Med Chem. 2020;63(1):321–333.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Trallori E, Singh S, Lomelino CL, Bartolucci G. 4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles. J Med Chem. 2018;61(23):10860–10874.
   PubMed Web of Science ®Google Scholar
• Lomelino CL, Murray AB, Supuran CT, Sweet Binders: MR. Carbonic Anhydrase IX in Complex with Sucralose. ACS Med Chem Lett. 2018;9(7):657–661.
   PubMed Web of Science ®Google Scholar
• Murray AB, Lomelino CL, Supuran CT, McKenna R. “Seriously Sweet”: acesulfame K Exhibits Selective Inhibition Using Alternative Binding Modes in Carbonic Anhydrase Isoforms. J Med Chem. 2018;61(3):1176–1181.
   PubMed Web of Science ®Google Scholar
• Mboge MY, Mahon BP, Lamas N, et al. Structure activity study of carbonic anhydrase IX: selective inhibition with ureido-substituted benzenesulfonamides. Eur J Med Chem. 2017;132:184–191.
   PubMed Web of Science ®Google Scholar
• Moeker J, Mahon BP, Bornaghi LF, et al. Structural insights into carbonic anhydrase IX isoform specificity of carbohydrate-based sulfamates. J Med Chem. 2014;57(20):8635–8645.
   PubMed Web of Science ®Google Scholar
• Jonsson BH, Liljas A. Perspectives on the Classical Enzyme Carbonic Anhydrase and the Search for Inhibitors. Biophys J. 2020;119:1275–1280.
   PubMed Web of Science ®Google Scholar
• Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev. 2020;40:2485–2565.
   PubMed Web of Science ®Google Scholar
• Nguyen GTH, Tran TN, Podgorski MN, Bell SG, Supuran CT, Donald WA. Nanoscale Ion Emitters in Native Mass Spectrometry for Measuring Ligand-Protein Binding Affinities. ACS Cent Sci. 2019;5(2):308–318.
   Web of Science ®Google Scholar
• Nguyen GTH, Nocentini A, Angeli A, Gratteri P, Supuran CT, Donald WA. Perfluoroalkyl Substances of Significant Environmental Concern Can Strongly Inhibit Human Carbonic Anhydrase Isozymes. Anal Chem. 2020;92(6):4614–4622.
   Web of Science ®Google Scholar
• Nguyen GTH, Leung WY, Tran TN, Wang H, Murray V, Donald WA. Mechanism for the Binding of Netropsin to Hairpin DNA Revealed Using Nanoscale Ion Emitters in Native Mass Spectrometry. Anal Chem. 2020;92(1):1130–1137.
   Web of Science ®Google Scholar
• D’Ambrosio K, Carradori S, Monti SM, et al. Out of the active site binding pocket for carbonic anhydrase inhibitors. Chem Commun. 2015;51:302–305.
   PubMed Web of Science ®Google Scholar